Compare ImmunityBio Inc. Common Stock (IBRX) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs Workiva Inc — how do they compare? ImmunityBio Inc. Common Stock trades at $9.99 (market cap $10.33B), while Workiva Inc trades at $75.4 (market cap $3.89B). The key difference: ImmunityBio Inc. Common Stock is far larger — about 2.7× Workiva Inc's market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and Workiva Inc for 21 Days on average.
| IBRX | WK | |
|---|---|---|
Market Cap | $10.33B | $3.89B |
Volume | 11,745,198 | 1,378,359 |
Sector | Health | Technology |
52-Week High | $11.55 | $93.31 |
52-Week Low | $1.98 | $44.31 |
Typical Hold Time | 0 Days | 21 Days |
Enterprise Value | $10.79B | $3.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Workiva (WK) trades at $71.53, up 1.95% with a bullish technical signal supported by moving averages. The company shows strong revenue growth with 2026 revenue reaching $966 million and net income turning positive at $47 million. Recent earnings beats and AI product innovations at Amplify 2026 conference highlight operational momentum. Analyst consensus remains strongly bullish with 16 buy ratings and an $86 price target representing 20% upside potential from current levels.
The outlook remains positive with continued earnings growth and AI-driven product expansion driving potential upside. Key risks include high valuation multiples (P/E 85.15) and competitive pressures in the regulatory technology space. The stock's technical positioning near support at $71 suggests near-term stability, while fundamental improvements support longer-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
